Human monoclonal antibodies against monkeypox virus and other orthopoxviruses
Human monoclonal antibodies derived from memory B cells of vaccinated or naturally infected donors neutralize and bind to monkeypox, vaccinia, and cowpox viruses, addressing the lack of treatments for Orthopoxvirus infections and offering broad-spectrum protection and therapy.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- FOND TOSCANA LIFE SCI
- Filing Date
- 2025-12-17
- Publication Date
- 2026-07-02
AI Technical Summary
There are no approved specific treatments for monkeypox virus infections, and the discontinuation of smallpox vaccination has left a significant portion of the human population vulnerable to Orthopoxvirus infections, necessitating the development of novel, safe, and highly immunogenic human monoclonal antibodies for prevention and therapeutic intervention.
Isolation, production, and characterization of human monoclonal antibodies with neutralizing and cross-neutralizing activity against monkeypox, vaccinia, and cowpox viruses, derived from memory B cells of donors recovered from natural infections or immunized with the MVA-BN vaccine, using a method involving PBMCs, cell sorting, cytokine culture, and recombinant IgG1 expression.
The developed monoclonal antibodies effectively neutralize and bind to multiple poxviruses, providing broad-spectrum protection and therapeutic benefits, suitable for prophylaxis and treatment of poxvirus infections, including novel outbreaks, with high inhibitory concentrations against monkeypox, vaccinia, and cowpox viruses.
Smart Images
Figure IMGF000017_0001_TABLE 
Figure IMGF000025_0001_TABLE 
Figure IMGF000026_0001_TABLE